{"schema_version":"secwatch.filing_event.v1","accession":"0001728117-21-000103","form_type":"8-K","ticker":"GOSS","cik":"0001728117","company_name":"Gossamer Bio, Inc.","filed_at":"2021-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.859924+00:00","generated_at":"2026-06-28T11:38:26.886912+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Gossamer Q3 net loss $60.2M ($0.80/shr); PAH study topline delayed to H2 2022","bullets":["Net loss $60.2M for Q3 2021 vs $57.8M prior year, R&D $43.2M, G&A $12.5M.","Cash, equivalents and securities $366M as of Sept 30, 2021; sufficient into H2 2023.","Phase 2 TORREY (PAH) topline results now expected H2 2022 due to COVID-19 delays.","Phase 2 SHIFT-UC (ulcerative colitis) completed enrollment; topline Q2, treat-through data Q4 2022.","GB5121 advanced to Phase 1 healthy volunteers; GB7208 (MS) Phase 1 expected H2 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001728117-21-000103","json":"https://secwatch.observer/filing/0001728117-21-000103.json","markdown":"https://secwatch.observer/filing/0001728117-21-000103.md","text":"https://secwatch.observer/filing/0001728117-21-000103.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728117/000172811721000103/0001728117-21-000103-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728117/000172811721000103/goss-20211108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T11:38:26.886912+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}